



Discarded Drug Refund CY 2023 New Refund Quarters

Generally, when a separately payable drug from a single-dose container or single-use package is administered to an individual enrolled in Medicare Part B, Medicare pays the provider or facility for both administered and discarded amounts of the drug, up to the labeled amount of the product. Section 90004 of the IIJA ([Pub. L. 117-58](#), November 15, 2021) amended section 1847A of the Social Security Act (the Act) by adding provisions that require manufacturers to provide a refund to CMS for certain discarded amounts from a single-dose container or single-use package drug. Generally, the refund amount is the amount of payment for discarded amounts of a refundable drug (described below) that exceeds an applicable percentage, which is required to be at least 10 percent of total charges for the drug in a given calendar quarter. For specific calculations for new refund quarters and updated refund quarters, refer to 42 CFR 414.940(c).

CMS sent discarded drug refund reports for CY 2023 “new refund quarters” (as defined at § 414.902) in December of 2024. Below are the billing and payment codes for which a manufacturer (or manufacturers) paid a refund, and the combined amount of refund paid for the all four new refund quarters in 2023. These funds were deposited into the Supplementary Medical Insurance (SMI) trust fund, as required by law. The total refunds owed for new refund quarters in 2023 amounts to **over \$139 million**.

Billing and Payment Code	Code Description	Refund Paid for New Refund Quarters in CY 2023
C9482	INJECTION, SOTALOL HYDROCHLORIDE, 1 MG	\$139,168.61
J0122	INJECTION, ERAVACYCLINE, 1 MG	\$3,411.96
J0172	INJECTION, ADUCANUMAB-AVWA, 2 MG	\$768.77
J0485	INJECTION, BELATACEPT, 1 MG	\$5,812,296.07
J0565	INJECTION, BEZLOTOXUMAB, 10 MG	\$1,027,806.02
J0585	INJECTION, ONABOTULINUMTOXINA, 1 UNIT	\$1,538,243.80
J0642	INJECTION, LEVOLEUCOVORIN (KHAPZORY), 0.5 MG	\$12,164.00
J0699	INJECTION, CEFIDEROCOL, 10 MG	\$64.97
J0712	INJECTION, CEFTAROLINE FOSAMIL, 10 MG	\$10,034.03
J0877	INJECTION, DAPTOMYCIN (HOSPIRA), NOT THERAPEUTICALLY EQUIVALENT TO J0878, 1 MG	\$3,882.39
J0893	INJECTION, DECITABINE (SUN PHARMA), NOT THERAPEUTICALLY EQUIVALENT TO J0894, 1 MG	\$1,134.44
J1448	INJECTION, TRILACICLIB, 1MG	\$2,281,170.85
J2358	INJECTION, OLANZAPINE, LONG-ACTING, 1 MG	\$472.26
J2562	INJECTION, PLERIXAFOR, 1 MG	\$703,682.37
J2796	INJECTION, ROMIPLOSTIM, 10 MICROGRAMS	\$10,409,899.25

J2993	INJECTION, RETEPLASE, 18.1 MG	\$2,512.49
J2997	INJECTION, ALTEPLASE RECOMBINANT, 1 MG	\$136,674.70
J3101	INJECTION, TENECTEPLASE, 1 MG	\$8,582,299.78
J3241	INJECTION, TEPROTUMUMAB-TRBW, 10 MG	\$7,814,704.00
J3396	INJECTION, VERTEPORFIN, 0.1 MG	\$126,387.13
J7665	MANNITOL, ADMINISTERED THROUGH AN INHALER, 5 MG	\$13.30
J9037	INJECTION, BELANTAMAB MAFODOTIN-BLMF, 0.5 MG	\$42,381.98
J9042	INJECTION, BRENTUXIMAB VEDOTIN, 1 MG	\$6,705,133.76
J9043	INJECTION, CABAZITAXEL, 1 MG	\$27,560,349.03
J9071	INJECTION, CYCLOPHOSPHAMIDE (AUROMEDICS), 5 MG	\$17,215.60
J9179	INJECTION, ERIBULIN MESYLATE, 0.1 MG	\$1,063,439.40
J9205	INJECTION, IRINOTECAN LIPOSOME, 1 MG	\$2,099,532.65
J9223	INJECTION, LURBINECTEDIN, 0.1 MG	\$14,700,008.51
J9228	INJECTION, IPILIMUMAB, 1 MG	\$15,098,915.31
J9229	INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG	\$2,725,399.32
J9264	INJECTION, PACLITAXEL PROTEIN-BOUND PARTICLES, 1 MG	\$13,964,619.06
J9266	INJECTION, PEGASPARGASE, PER SINGLE DOSE VIAL	\$4,715.40
J9273	INJECTION, TISOTUMAB VEDOTIN-TFTV, 1 MG	\$2,868.30
J9281	MITOMYCIN PYELOALYCEAL INSTILLATION, 1 MG	\$3,809,203.60
J9295	INJECTION, NECITUMUMAB, 1 MG	\$1,009.71
J9307	INJECTION, PRALATREXATE, 1 MG	\$1,334,336.61
J9314	INJECTION, PEMETREXED (TEVA), NOT THERAPEUTICALLY EQUIVALENT TO J9305, 10 MG	\$68.35
J9328	INJECTION, TEMOZOLOMIDE, 1 MG	\$624.66
J9332	INJECTION, EFGARTIGIMOD ALFA-FCAB, 2MG	\$3,932,602.15
J9352	INJECTION, TRABECTEDIN, 0.1 MG	\$207,039.58
J9359	INJECTION, LONCASTUXIMAB TESIRINE-LPYL, 0.075 MG	\$7,178,882.58
J9400	INJECTION, ZIV-AFLIBERCEPT, 1 MG	\$6,906.14
	TOTAL	\$139,062,042.89